What does Pell Bio-Med Technology Co., Ltd. do?

Pell Bio-Med Technology Co., Ltd. (6949.TW) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6949.TW's market cap?

Pell Bio-Med Technology Co., Ltd. (6949.TW) has a market capitalization of approximately $97.65 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6949.TW pay a dividend?

No — Pell Bio-Med Technology Co., Ltd. (6949.TW) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6949.TW profitable?

Pell Bio-Med Technology Co., Ltd. (6949.TW) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6949.TW

Pell Bio-Med Technology Co., Ltd.

TAI·Biotechnology · Healthcare

NT$1,490.00NT$135.00+9.96%

Market capNT$97.65B·Market closed·Aug 26 5:30 AM UTC

Price Chart

NT$1,490.00+NT$135.00 (+9.96%)today

+1,346.60%CAGR +195.38%

Select date range

FromTo

Mar 8, 2024Mar 8, 2024 → Aug 26, 2026· 2.5 yrsAug 26, 2026

Key Metrics

6949.TW does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateAug 6

Last Report DateAug 5

Reported vs Estimate−NT$1.36

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$28.93M

Net Income−NT$451.13M

Net Margin−1,559.5%

Operating Cash Flow−NT$399.90M

Capital ExpendituresNT$228.17M

Free Cash Flow−NT$628.07M

Return on Equity−17.5%

Return on Invested Capital−3.6%

Net CashNT$2.04B

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6949.TW and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6949.TW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6949.TW and 80,000+ other tickers.

About Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell…

CEO: Cheng Long Lin
Sector: Healthcare
Industry: Biotechnology
Exchange: TAI
Employees: 94
Website: www.pellbmt.com

Peers

Sunmax Biotechnology Co., Ltd.

Cap

NT$21.8B

4147.TWO

TaiMed Biologics Inc.

Cap

NT$17.8B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6949.TW

What does Pell Bio-Med Technology Co., Ltd. do?: Pell Bio-Med Technology Co., Ltd. (6949.TW) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6949.TW's market cap?: Pell Bio-Med Technology Co., Ltd. (6949.TW) has a market capitalization of approximately $97.65 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6949.TW pay a dividend?: No — Pell Bio-Med Technology Co., Ltd. (6949.TW) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6949.TW profitable?: Pell Bio-Med Technology Co., Ltd. (6949.TW) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.